MSK immunologist Dr. Andrea Schietinger and colleagues found that a 'triad' of immune cells is required to kill cancer cells.
GSK alum Dr. Ellen Horste’s time investigating fundamental biological questions prepared her for a career in the emerging ...
A recent study led by investigators at MSK and published in Nature Medicine, included a comprehensive analysis of non relapse ...
Exercise scientist Lee Jones, PhD, led a first-of-its-kind clinical trial to investigate how exercise may affect treatment for prostate cancer at Memorial Sloan Kettering Cancer Center. “We believe ...
MSK researchers have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
Thoracic surgeon Gaetano Rocco, MD, holding a component of the "E-Nose," a noninvasive lung cancer test that produced promising results in a clinical trial at Memorial Sloan Kettering. Detecting lung ...
The FDA has granted full approval to the targeted therapy selpercatinib (Retevmo®) for treating thyroid cancers that have certain changes in a gene called RET. Learn about MSK’s role in the ...
Post-transplantation cyclophosphamide (PTCy) led to similar overall survival (OS) and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) in patients who received a hematopoietic stem ...